Janney Montgomery Scott LLC Increases Stake in Becton, Dickinson and Company $BDX

Janney Montgomery Scott LLC boosted its position in Becton, Dickinson and Company (NYSE:BDX) by 11.7% during the first quarter, HoldingsChannel reports. The fund owned 186,612 shares of the medical instruments supplier’s stock after buying an additional 19,481 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Becton, Dickinson and Company were worth $29,341,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in BDX. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company in the third quarter worth about $25,000. Steph & Co. boosted its holdings in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the period. SHP Wealth Management purchased a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $29,000. Finally, WPG Advisers LLC lifted its position in shares of Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 61 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $154.81 on Tuesday. The stock has a market cap of $42.66 billion, a price-to-earnings ratio of 39.19, a PEG ratio of 11.04 and a beta of 0.22. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The business has a 50-day simple moving average of $148.16 and a 200 day simple moving average of $170.37. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter last year, the firm posted $3.35 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, research analysts forecast that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, June 9th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Zacks Research upgraded Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Barclays increased their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a report on Monday, May 11th. Bank of America reduced their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Finally, Weiss Ratings cut shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. Seven research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $181.00.

Insider Buying and Selling

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,188 shares of company stock valued at $765,120. Corporate insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.